Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

A user shared their hair loss treatment regimen, which includes minoxidil, finasteride, ketoconazole shampoo, stemoxydine, and microneedling, and reported promising results. Other users complimented the progress.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

A 46-year-old shared 1.6 years of hair regrowth progress using a regimen that includes Minoxidil, Finasteride, and possibly other treatments. Suggestions included considering a hair transplant, using dutasteride, and adding tretinoin for further improvement.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The user is using a combination of finasteride, dutasteride, oral and topical minoxidil, PRP, and stem cell treatments for hair loss. They report slowed shedding and new vellus hairs on the hairline, questioning if they are a strong responder to the treatment.

VDPHL01 is discussed as a potential replacement for DHT blockers, with comparisons to minoxidil. Users express skepticism about its effectiveness without addressing DHT, suggesting it may only slow hair loss rather than stop it.

The conversation discusses reliable brands for RU58841, with recommendations for RUdirect and Receptorchem. Users also mention Anageninc as a known option for RU58841 in Europe and the UK.

RU58841 is used to eliminate scalp itch. Users discuss difficulty finding reliable and affordable sources.

A 38-year-old discusses hair loss treatments, including two hair transplants, daily oral Dutasteride, oral Minoxidil, topical RU58841, Pyrilutamide, and microneedling. They noticed increased hair thinning despite these treatments.

The conversation is about finding a reliable source for purchasing RU58841 in Europe. Users discuss the legitimacy of different websites for ordering the product.

A 36-year-old male using dutasteride and minoxidil has seen significant hair regrowth, confirmed by a dermatologist and supported by before-and-after photos. He plans to increase his oral minoxidil dosage and add dermapen to his routine.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

RU-58841 users in Canada discuss their experiences, with some reporting positive results and others experiencing side effects. Users also share sources for purchasing RU-58841 and related solvents, with AnagenInc being a common supplier.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

A 35-year-old man underwent a 6400 graft DHI hair transplant in Turkey, combined with scalp micropigmentation (SMP), to address severe hair loss from Norwood 7. He uses finasteride, oral and topical minoxidil, and GHK-CU, and is satisfied with the results, noting improved hair coverage and confidence despite some remaining thin areas.

RU58841 shows the strongest results despite weaker binding affinity, while KX-826 and CB-03-01 are more expensive and have minimal side effects. RU58841 is considered effective but has potential health risks if ingested; users report positive outcomes with RU58841 and finasteride.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

A 29-year-old man is happy with his hair transplant results, using 2.5mg minoxidil and 1mg finasteride orally, along with a multivitamin. The transplant focused on the hairline and first-third of the head, with medication helping to fill in the crown area.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.